Zevra Therapeutics, Inc. ZVRA Operating Lease Liabilities (Current)

Operating Lease Liabilities (Current) at other companies

Rigel PharmaceuticalsRIGL

$636K+39.5%

Theravance BiopharmaTBPH

$10.8M-0.9%

XER

Xeris Biopharma Holdings, Inc.XERS

$6.31M+2.5%

Eton Pharmaceuticals, Inc.ETON

$75K-2.6%

Relay Therapeutics, Inc.RLAY

$4.01M+13.9%

PVL

Palvella TherapeuticsPVLA

$209K—

FAQ

What is Zevra Therapeutics, Inc.'s operating lease liabilities (current)?

Zevra Therapeutics, Inc. (ZVRA) reported operating lease liabilities (current) of $626K in Q2 2026.

How has Zevra Therapeutics, Inc.'s operating lease liabilities (current) changed year-over-year?

Zevra Therapeutics, Inc.'s operating lease liabilities (current) increased by 19.2% year-over-year, from $525K to $626K.

What is the long-term trend for Zevra Therapeutics, Inc.'s operating lease liabilities (current)?

Over 5 years (2020 to 2025), Zevra Therapeutics, Inc.'s operating lease liabilities (current) has grown at a 5.1% compound annual growth rate (CAGR), from $327K to $419K.

What does operating lease liabilities (current) mean?

The current portion of operating lease obligations due within one year, representing committed future lease payments under ASC 842.